2 FDA committee members resign over Biogen Alzheimer's drug approval

Fallout over the FDA’s recent decision to grant Biogen’s Alzheimer’s drug accelerated approval has seen two advisory panel members resign.

"I was very disappointed at how the advisory committee input was treated by the FDA," Knopman told the outlet. "I don’t wish to be put in a position like this again."  The other member is Dr. Joel Perlmutter, a neurologist of Washington University in St Louis, who told STAT that his resignation on Monday was "due to this ruling by the FDA without further discussion with our advisory committee."